Prognostic signature for pancreatic cancer: Are we close?

Future Oncology

Volumn 5, Issue 3, 2009, Pages 313-321

  Yeh, Jen Jen ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Gene expression; Pancreatic cancer; Prognosis

Indexed keywords

ERLOTINIB; GEMCITABINE;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION PROFILING; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 66949132138     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.12     Document Type: Review

References (78)

1. Boyle P, Levin B; IARC: World Cancer Report 2008 (International Agency for Research on Cancer) (2008).
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
3. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
4. Kolbert CP, Chari S, Sreekumar R: Microarray technologies for gene transcript analysis in pancreatic cancer. Tecbnol. Cancer Res. Treat. 7(1), 55-59 (2008).
5. Grutzmann R, Boriss H, Ammerpohl O et al.: Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24(32), 5079-5088 (2005).
6. Grutzmann R, Saeger HD, Luttges J et al.: Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. Int. J. Colorectal Dis. 19(5), 401-413 (2004).
7. Goggins M: Identifying molecular markers for the early detection of pancreatic neoplasia. Semin. Oncol. 34(4), 303-310 (2007).
8. Grote T, Logsdon CD: Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 23(5), 508-514 (2007).
9. Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D: Molecular prognostic factors in patients with pancreatic cancer. Expert Opin. Ther. Targets 11(12), 1553-1569 (2007).
10. Sebolt-Leopold JS, English JM: Mechanisms of drug inhibition of signaling molecules. Nature 441(7092), 457-462 (2006).
11. Garber K: The second wave in kinase cancer drugs. Nat. Biotechnol. 24(2), 127-130 (2006).
12. Moore MJ, Goldstein D, Hamm J et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
13. Welch SA, Moore MJ: Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol. 3(3), 247-254 (2007).
14. De Roock W, Piessevaux H, De Schutter J et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008).
15. Eberhard DA, Johnson BE, Amler LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
16. Lievre A, Bachet JB, Boige V et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008).
17. Zhu CQ, da Cunha Santos G, Ding K et al.: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26(26), 4268-4275 (2008).
18. Jones S, Zhang X, Parsons DW et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
19. Yeh JJ, Der CJ: Targeting signal transduction in pancreatic cancer treatment. Expert Opin. Ther. Targets 11(5), 673-694 (2007).
20. Diamantidis M, Tsapournas G, Kountouras J, Zavos C: New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr. Mol. Med. 8(1), 12-37 (2008).
21. Sarkar FH, Li YW: Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol. Sin. 28(9), 1305-1315 (2007).
22. Holloway AJ, van Laar RK, Tothill RW, Bowtell DD: Options available - from start to finish - for obtaining data from DNA microarrays II. Nat. Genet. 32(Suppl.), 481-489 (2002).
23. Quackenbush J: Microarray analysis and tumor classification. N. Engl. J. Med. 354(23), 2463-2472 (2006).
24. Breitling R: Biological microarray interpretation: the rules of engagement. Biochim. Biophys. Acta 1759(7), 319-327 (2006).
25. Hezel AF, Bardeesy N: Prognostic markers in pancreatic ductal adenocarcinomas. Cancer Biol. Ther. 7(9), 1360-1361 (2008).
26. Neuhaus P, Riess H, Post S et al.: CONKO-001: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J. Clin. Oncol. 26(Suppl.), LBA4504 (2008).
27. Ferrone CR, Brennan MF, Gotten M et al.: Pancreatic adenocarcinoma: the actual 5-year survivors. J. Gastrointest. Surg. 12(4), 701-706 (2008).
28. Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. 223(3), 273-279 (1996).
29. Schnelldorfer T, Ware AL, Sarr MG et al.: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann. Surg. 247(3), 456-462 (2008).
30. Cleary SP, Gryfe R, Guindi M et al.: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J. Am. Coll. Surg. 198(5), 722-731 (2004).
31. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH: Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32(3), 271-275 (2006).
32. Winter JM, Cameron JL, Campbell KA et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J. Gastrointest. Surg. 10(9), 1199-1210; discussion 1210-1191 (2006).
33. Ahmad NA, Lewis JD, Ginsberg GG et al.: Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am. J. Gastroenterol. 96(9), 2609-2615 (2001).
34. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
35. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA, 98(19), 10869-10874 (2001).
36. Rouzier R, Perou CM, Symmans WF et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11(16), 5678-5685 (2005).
37. Tothill RW, Tinker AV, George J et al.: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14(16), 5198-5208 (2008).
38. Eschrich S, Yang I, Bloom G et al.: Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23(15), 3526-3535 (2005).
39. Gascoyne RD: Emerging prognostic factors in diffuse large B cell lymphoma. Curr. Opin. Oncol. 16(5), 436-441 (2004).
40. Shedden K, Taylor JM, Enkemann SA et al.: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14(8), 822-827 (2008).
41. Friess H, Ding J, Kleeff J et al.: Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol. Life Sci. 60(6), 1180-1199 (2003).
42. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62(10), 2890-2896 (2002).
43. Zhou W, Sokoll LJ, Bruzek DJ et al.: identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol. Biomarkers Prev. 7(2), 109-112. (1998).
44. Lowe AW, Olsen M, Hao Y et al.: Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE, 2, E323 (2007).
45. Iacobuzio-Donahue CA, Maitra A, Olsen M et al.: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 162(4), 1151-1162 (2003).
46. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al.: Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160(4), 1239-1249 (2002).
47. Karanjawala ZE, Illei PB, Ashfaq R et al.: New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin AS. Am. J. Surg. Pathol. 32(2), 188-196 (2008).
48. Koopmann J, Fedarko NS, Jain A et al.: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 13(3), 487-491 (2004).
49. Koopmann J, Buckhaults P, Brown DA et al.: Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10(7), 2386-2392 (2004).
50. Segara D, Biankin AV, Kench JG et al.: Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin. Cancer Res. 11(9), 3587-3596 (2005).
51. Pasca di Magliano M, Biankin AV, Heiser PW et al.: Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2(11), E1155 (2007).
52. Logsdon CD, Simeone DM, Binkley C et al.: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63(10), 2649-2657 (2003).
53. Sclabas GM, Fujioka S, Schmidt C et al.: Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin. Cancer Res. 11(2 Pt 1), 440-449 (2005).
54. Grutzmann R, Foerder M, Alldinger I et al.: Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch. 443(4), 508-517 (2003).
55. Collisson EA, Das D, Mori R et al.: Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after surgery. J. Clin. Oncol. 26(Suppl.), 4503 (2008).
56. Kim HN, Choi DW, Lee KT et al.: Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas 34(3), 325-334 (2007).
57. Sohn TA, Yen CJ, Cameron JL et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4(6), 567-579 (2000).
58. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306), 893-895 (1977).
59. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33(1), 49-54 (2003).
60. Niedergethmann M, Alves F, Neff JK et al.: Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br. J. Cancer 97(10), 1432-1440 (2007).
61. Thakur A, Bollig A, Wu J, Liao DJ: Gene expression profiles in primary pancreatic tumors and metastatic lesions of Ela-c-myc transgenic mice. Mol. Cancer 7, 11 (2008).
62. Campagna D, Cope L, Lakku, SS, Henderson C, Laheru D, Iacobuzio-Donahue CA: Gene expression profiles associated with advanced pancreatic cancer. Int. J. Clin. Exp. Pathol. 1(1), 32-43 (2008).
63. Chung MT, Lai HC, Sytwu HK et al.: SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol. Oncol. 112(3), 646-653 (2008).
64. van Kempen LC, Coussens LM: MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2(4), 251-252 (2002).
65. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100(26), 15901-15905 (2003).
66. Weigelt B, Hu Z, He X et al.: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65(20), 9155-9158 (2005).
67. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al.: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63(24), 8614-8622 (2003).
68. Morente MM, Fernandez PL, de Alava E: Biobanking: old activity or young discipline? Semin. Diagn. Pathol. 25(4), 317-322 (2008).
69. Mahadevan D, Von Hoff DD: Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6(4), 1186-1197 (2007).
70. Nakamura T, Furukawa Y, Nakagawa H et al.: Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23(13), 2385-2400 (2004).
71. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al.: Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20(50), 7437-7446 (2001).
72. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T et al.: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21(29), 4587-4594 (2002).
73. Mori R, Collisson EA, Hoffmann AC et al.: Different pancreatic cancer genomic risk prediction models derived from microdissected and non-microdissected paraffin-embedded tissue. J. Clin. Oncol. 26(Suppl.), 4622 (2008).
74. Bhowmick NA, Chytil A, Plieth D et al.: TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (5659), 848-851 (2004).
75. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332-337 (2004).
76. Hwang RF, Moore T, Arumugam T et al.: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68(3), 918-926 (2008).
77. Fukushima N, Koopmann J, Sato N et al.: Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod. Pathol. 18(6), 779-787 (2005).
78. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE: Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am. J. Pathol. 160(1), 91-99 (2002).